BEAM
Price
$20.75
Change
+$0.30 (+1.47%)
Updated
Jul 18 closing price
Capitalization
2.09B
22 days until earnings call
NUVB
Price
$2.42
Change
+$0.12 (+5.22%)
Updated
Jul 21, 10:34 AM (EDT)
Capitalization
782.6M
16 days until earnings call
Interact to see
Advertisement

BEAM vs NUVB

Header iconBEAM vs NUVB Comparison
Open Charts BEAM vs NUVBBanner chart's image
Beam Therapeutics
Price$20.75
Change+$0.30 (+1.47%)
Volume$2.18M
Capitalization2.09B
Nuvation Bio
Price$2.42
Change+$0.12 (+5.22%)
Volume$13.11K
Capitalization782.6M
BEAM vs NUVB Comparison Chart in %
Loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NUVB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BEAM vs. NUVB commentary
Jul 21, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Hold and NUVB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 21, 2025
Stock price -- (BEAM: $20.75 vs. NUVB: $2.30)
Brand notoriety: BEAM and NUVB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 109% vs. NUVB: 72%
Market capitalization -- BEAM: $2.09B vs. NUVB: $782.6M
BEAM [@Biotechnology] is valued at $2.09B. NUVB’s [@Biotechnology] market capitalization is $782.6M. The market cap for tickers in the [@Biotechnology] industry ranges from $286.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 1 FA rating(s) are green whileNUVB’s FA Score has 0 green FA rating(s).

  • BEAM’s FA Score: 1 green, 4 red.
  • NUVB’s FA Score: 0 green, 5 red.
According to our system of comparison, both BEAM and NUVB are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 6 TA indicator(s) are bullish while NUVB’s TA Score has 6 bullish TA indicator(s).

  • BEAM’s TA Score: 6 bullish, 3 bearish.
  • NUVB’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, both BEAM and NUVB are a good buy in the short-term.

Price Growth

BEAM (@Biotechnology) experienced а -1.94% price change this week, while NUVB (@Biotechnology) price change was +4.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.68%. For the same industry, the average monthly price growth was +13.07%, and the average quarterly price growth was +34.43%.

Reported Earning Dates

BEAM is expected to report earnings on Aug 12, 2025.

NUVB is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+2.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($2.09B) has a higher market cap than NUVB($783M). NUVB YTD gains are higher at: -13.534 vs. BEAM (-16.331). BEAM has higher annual earnings (EBITDA): -399.03M vs. NUVB (-605.05M). BEAM has more cash in the bank: 1.22B vs. NUVB (462M). NUVB has less debt than BEAM: NUVB (11.4M) vs BEAM (158M). BEAM has higher revenues than NUVB: BEAM (63.6M) vs NUVB (11M).
BEAMNUVBBEAM / NUVB
Capitalization2.09B783M267%
EBITDA-399.03M-605.05M66%
Gain YTD-16.331-13.534121%
P/E RatioN/AN/A-
Revenue63.6M11M578%
Total Cash1.22B462M264%
Total Debt158M11.4M1,386%
TECHNICAL ANALYSIS
Technical Analysis
BEAMNUVB
RSI
ODDS (%)
Bearish Trend 4 days ago
83%
Bullish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
87%
Momentum
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 4 days ago
82%
MACD
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
83%
Bullish Trend 4 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
81%
Advances
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
79%
Declines
ODDS (%)
N/A
Bearish Trend 7 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
75%
Bearish Trend 4 days ago
88%
Aroon
ODDS (%)
Bullish Trend 4 days ago
76%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NUVB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TRXIX12.240.04
+0.33%
Catalyst/MAP Global Balanced I
PGWAX96.150.04
+0.04%
Virtus Silvant Focused Growth A
BSTSX70.73-0.17
-0.24%
BlackRock Technology Opportunities Svc
WGICX7.73-0.06
-0.77%
Wasatch Micro Cap Institutional
MASOX10.20-0.08
-0.78%
MoA Small Cap Equity Index Fund

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
+1.47%
CRSP - BEAM
70%
Closely correlated
+18.22%
NTLA - BEAM
65%
Loosely correlated
+1.94%
RXRX - BEAM
64%
Loosely correlated
+5.80%
DNLI - BEAM
63%
Loosely correlated
-3.65%
SYRE - BEAM
59%
Loosely correlated
-3.55%
More

NUVB and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVB has been loosely correlated with XNCR. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVB jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVB
1D Price
Change %
NUVB100%
+2.68%
XNCR - NUVB
48%
Loosely correlated
-1.10%
BEAM - NUVB
47%
Loosely correlated
+1.47%
DNLI - NUVB
47%
Loosely correlated
-3.65%
ERAS - NUVB
46%
Loosely correlated
+0.67%
MNMD - NUVB
45%
Loosely correlated
N/A
More